Recent Advances in ROS-Sensitive Nano-Formulations for Atherosclerosis Applications

Ji, Hao; Peng, Renyi; Jin, Libo; Ma, Jiahui; Yang, Qinsi; Sun, Da; Wu, Wei

doi:10.3390/pharmaceutics13091452

Cited by 14 publications

(12 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The accumulation of ROS in atherosclerotic endothelial injury promotes macrophage foaming, stimulates their production of pro-inflammatory cytokines and chemokines, and enhances the inflammatory activity of macrophages. Excessive ROS accumulation also induces vascular cell damage, inflammatory cell recruitment, lipid peroxidation, metalloproteinase activation, and extracellular matrix deposition, which together lead to vascular remodeling [ 30 ] [ 31 ]. Nitric oxide (NO) is a multifunctional signaling molecule, which has a number of intracellular effects that lead to vasorelaxation, endothelial regeneration, inhibition of leukocyte chemotaxis, and platelet adhesion [ 32 , 33 ].…”

Section: Resultsmentioning

confidence: 99%

Pro-efferocytic macrophage membrane biomimetic nanoparticles for the synergistic treatment of atherosclerosis via competition effect

et al. 2022

View full text Add to dashboard Cite

Macrophages participate in many links in the pathological process of atherosclerosis (AS) and the regulation of influence of macrophages at the molecular level might be a new avenue for AS treatment. For this aim, the macrophage membrane biomimetic nanoparticles, derived from macrophage membrane coated SHP1i-loaded liposome NPs (MM@Lips-SHP1i) was designed. Due to the reservation of intrinsic membrane proteins and function from macrophages, the biomimic nanoparticles could effectively evade clearance by the immune system, prolong blood circulation time and actively tend and aggregate to atherosclerotic plaques. More importantly, in the plaque area, MM@Lips-SHP1i nanoparticles could compete with macrophages in vivo to bind with oxidized low-density lipoprotein (oxLDL) and lipopolysaccharide (LPS), reduce uptake of new lipids by macrophages, reduce foam cell formation, and inhibit the expression of pro-inflammatory cytokines. In addition, small molecule inhibitor of SHP-1, the downstream effector molecule of CD47 loaded in macrophage membrane biomimetic nanoparticles could interrupt CD47-SIRPα signal transduction in monocytes and macrophages, thereby enhancing the efferocytosis of macrophages, inhibiting the progression of plaque, achieving synergistic treatment of atherosclerosis. This work focuses on the key process in the formation of AS, macrophage foaming and chronic inflammation, and is based on the fact that macrophage membrane biomimetic nanoparticles can preserve the key surface proteins of macrophages closely related to the formation of AS, providing a new avenue to inhibit the progression of AS by utilizing the biological characteristics of macrophage membrane in macrophage membrane biomimetic nanoparticles.

show abstract

Section: Resultsmentioning

confidence: 99%

Pro-efferocytic macrophage membrane biomimetic nanoparticles for the synergistic treatment of atherosclerosis via competition effect

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In cardiomyocyte mitochondria, and increased ROS leads to the loss of mtDNA and increased autophagy [91]. Currently, ROS-targeted approaches are the most promising type of anti-atherosclerotic therapies [92].…”

Section: Mitochondrial Oxidative Stressmentioning

confidence: 99%

The Role of Mitochondrial DNA Mutations in Cardiovascular Diseases

Dabravolski

Khotina

Sukhorukov

et al. 2022

IJMS

View full text Add to dashboard Cite

Cardiovascular diseases (CVD) are one of the leading causes of morbidity and mortality worldwide. mtDNA (mitochondrial DNA) mutations are known to participate in the development and progression of some CVD. Moreover, specific types of mitochondria-mediated CVD have been discovered, such as MIEH (maternally inherited essential hypertension) and maternally inherited CHD (coronary heart disease). Maternally inherited mitochondrial CVD is caused by certain mutations in the mtDNA, which encode structural mitochondrial proteins and mitochondrial tRNA. In this review, we focus on recently identified mtDNA mutations associated with CVD (coronary artery disease and hypertension). Additionally, new data suggest the role of mtDNA mutations in Brugada syndrome and ischemic stroke, which before were considered only as a result of mutations in nuclear genes. Moreover, we discuss the molecular mechanisms of mtDNA involvement in the development of the disease.

show abstract

“… 332 Previous studies have shown that introduction of exogenous antioxidants into the biological system to scavenge excessive ROS is an effective approach to alleviate and prevent vascular diseases. 333 Additional research evidence has shown that nano-antioxidants have the excellent antioxidant capacity and superior tolerance to harsh microenvironments in comparison to their natural counterparts. 334 Besides, the role of mitochondrial dysfunction in vascular aging encourages the exploration of mitochondrial-targeted therapeutic modalities for the prevention and intervention of vascular aging-related diseases.…”

Section: Nanoparticle-based Therapeutic Methods For Vascular Aging-re...mentioning

confidence: 99%

Nanoparticles in the diagnosis and treatment of vascular aging and related diseases

Liu

2022

Sig Transduct Target Ther

View full text Add to dashboard Cite

Aging-induced alternations of vasculature structures, phenotypes, and functions are key in the occurrence and development of vascular aging-related diseases. Multiple molecular and cellular events, such as oxidative stress, mitochondrial dysfunction, vascular inflammation, cellular senescence, and epigenetic alterations are highly associated with vascular aging physiopathology. Advances in nanoparticles and nanotechnology, which can realize sensitive diagnostic modalities, efficient medical treatment, and better prognosis as well as less adverse effects on non-target tissues, provide an amazing window in the field of vascular aging and related diseases. Throughout this review, we presented current knowledge on classification of nanoparticles and the relationship between vascular aging and related diseases. Importantly, we comprehensively summarized the potential of nanoparticles-based diagnostic and therapeutic techniques in vascular aging and related diseases, including cardiovascular diseases, cerebrovascular diseases, as well as chronic kidney diseases, and discussed the advantages and limitations of their clinical applications.

show abstract

Recent Advances in ROS-Sensitive Nano-Formulations for Atherosclerosis Applications

Cited by 14 publications

References 119 publications

Pro-efferocytic macrophage membrane biomimetic nanoparticles for the synergistic treatment of atherosclerosis via competition effect

Pro-efferocytic macrophage membrane biomimetic nanoparticles for the synergistic treatment of atherosclerosis via competition effect

The Role of Mitochondrial DNA Mutations in Cardiovascular Diseases

Nanoparticles in the diagnosis and treatment of vascular aging and related diseases

Contact Info

Product

Resources

About